ANEB - NASDAQ
Anebulo Pharmaceuticals, Inc.
$1.72
-33%Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
At a Glance
Live SnapshotNo Investing Cash Flow Data
ANEB has not reported any investing cash flow values in the available annual periods.
Anebulo Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Anebulo Pharmaceuticals, Inc. Cash Flow Statement
ANEB • NASDAQ
| Anebulo Pharmaceuticals, Inc. Cash Flow Statement | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||
-8.5M | -8.2M | -11.7M | -6.8M | -30.3M | -174.6K | |
382K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
1.4M | 758.9K | 884.7K | 480.7K | 199.9K | 0.0 | |
0.0 | 151.2K | 731K | 209.9K | 26.6M | 7.7K | |
306.2K | -799.3K | 1.2M | 907.8K | -1.4M | 22.6K | |
-6.3M | -8.1M | -9.7M | -5.4M | -4.9M | -150.8K | |
INVESTING ACTIVITIES | ||||||
FINANCING ACTIVITIES | ||||||
14.9M | 0.0 | 6.6M | 0.0 | 22.9M | 3M | |
0.0 | 0.0 | 0.0 | 0.0 | -201.3K | 200K | |
0.0 | -62.4K | -264.7K | 0.0 | -821.6K | 0.0 | |
14.9M | -62.4K | 6.4M | 0.0 | 21.8M | 3.2M | |
CASH FLOW SUMMARY | ||||||
8.5M | -8.2M | -3.3M | -5.4M | 17M | 3M | |
3.1M | 11.2M | 14.5M | 20M | 3M | 0.0 | |
11.6M | 3.1M | 11.2M | 14.5M | 20M | 3M | |
-6.3M | -8.1M | -9.7M | -5.4M | -4.9M | -150.8K |
SEC Filings
ANEB - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2025 N/A | December 22, 2025 | December 22, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 13, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 13, 2025 | November 13, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 29, 2025 | September 29, 2025 | 2025 | |
10-K 10-K 2025 FY FY | September 29, 2025 | June 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 12, 2025 | September 12, 2025 | 2025 | |
8-K 8-K 2025 N/A | July 23, 2025 | July 23, 2025 | 2025 | |
10-Q 10-Q 2025 Q1 Q1 | May 13, 2025 | March 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | May 13, 2025 | May 13, 2025 | 2025 | |
8-K 8-K 2025 N/A | April 15, 2025 | April 11, 2025 | 2025 |
Related Guides
Continue your ANEB research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.